breast-cancer-congress-2017-posters-abstracts

10 / 15

Page 64
conferenceseries .com
6th World Congress on
October 16-18, 2017 | San Francisco, USA
Breast Cancer & Therapy
Volume 2, Issue 5 (Suppl) Breast Can Curr Res, an open access journal Breast Cancer Congress 2017
October 16-18, 2017
ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based
chemotherapy
Mohamed A Elbaiomy, Maha I El Zaafarany and Wagdi F Elkashef
Oncology Center Mansoura University, Egypt
Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic chemotherapy that
causes inter strand breaks (platinum-based drugs). The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential
role in the nucleotide excision repair pathway, removes platinum-induced DNA adducts and cisplatin resistance. Detecting ERCC1
overexpression is important in considering treatment option for metastatic TNBC, individualized approaches to therapy and may
improve response or reduce unnecessary toxicity. We hypothesized that assigning cisplatin based on pretreatment ERCC1 expression
would improve response and survival.
Aim: To assess the impact of ERCC1 expression on PFS, OS and response rate in metastatic triple negative breast cancer patients
treated with platinum-based chemotherapy.
Materials & Methods: From June 2012 to November 2013, 52 metastatic triple negative breast cancer patients were enrolled. ERCC1
protein expression was detected from pretreatment biopsies by Immunohistochemistry. All patients received cisplatin plus paclitaxel.
The primary end point was the impact of ERCC1 expression on PFS and OS.
Results: 34 patients (65.4%) showed positive ERCC1 expression while 18 patients (34.6%) showed negative ERCC1 expression.
Positive ERCC1 expression was associated with short PFS (median, 5 months vs. 7 months; P=0.043). Positive ERCC1 expression
was associated with short OS (median, 9 months vs. 11 months; P=0.033). Also, positive ERCC1 expression was associated with poor
response to cisplatin based chemotherapy (P=0.046).
Conclusions: This prospective study further validates ERCC1 as a reliable biomarker for customized chemotherapy in metastatic
triple negative breast cancer patients and shows that high expression of ERCC1 was significantly associated with poor outcome in
patients treated with platinum based chemotherapy.
Breast Can Curr Res 2017, 2:5 (Suppl)
DOI: 10.4172/2572-4118-C1-012